

STATE OF NEW YORK DEPARTMENT OF HEALTH

Wadsworth Center

The Governor Nelson A. Rockefeller Empire State Plaza

P.O. Box 509

Albany, New York 12201-0509

Richard F. Daines, M.D.
Commissioner

James W. Clyne, Jr.
Executive Deputy Commissioner

October 15, 2009

Dear Health Care Provider,

Beginning November 2, 2009, the New York Newborn Screening Program will modify its evaluation protocol for acylcarnitines as follows:

- The borderline cut-off for C8 will be raised from 0.30 to 0.35 $\mu\text{mole/L}$.
- The ratio C5OH/C8 will be used as a secondary marker for the evaluation of borderline specimens that may be consistent with 3-MCC/HMG/MGA.
- The cut-offs for C16 and C18:1 will be lowered from 10.00 to 8.00 and from 3.50 to 2.50 $\mu\text{mole/L}$, respectively. A low value of the ratio C0/(C16+C18) will be used as a secondary marker. Without a low secondary marker, a sample will not be considered abnormal. Any specimens with elevations of these markers will be referrals.
- The secondary marker for GA-I will be changed from the ratio C5DC/C3 to the ratio C5DC/C8.
- No referrals or requests for repeat specimens will be made solely on the basis of elevated C6DC levels. This compound will still be used as a secondary marker to differentiate between the conditions 3-MCC and HMG.

These changes should reduce the number of referrals and repeat requests made by the newborn screening program.

Thank you for your cooperation in making New York State Newborn Screening Program the best it can be. Questions can be directed to our main telephone number 518.473.7552.

Sincerely,



Michele Caggana, Sc.D., FACMG
Director,
Newborn Screening Program